LBA30ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) - Smith, M R; Parker, C C; Saad, F; Miller, K; Tombal, B; Ng, Q S; Bögemann, M; Matveev, V; Piulats, J M; Zucca, L E; Heidenreich, A; Kakehi, Y; et al.